.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,859,756

« Back to Dashboard

Details for Patent: 8,859,756

Title:Stereoselective synthesis of phosphorus containing actives
Abstract: Disclosed herein are phosphorus-containing actives, their use as actives for treating diseases, and a stereoselective process for preparing the same. Also disclosed herein are useful synthetic intermediates and processes for preparing the same.
Inventor(s): Ross; Bruce S. (Plainsboro, NJ), Sofia; Michael Joseph (Doylestown, PA), Pamulapati; Ganapati Reddy (Plainsboro, NJ), Rachakonda; Suguna (Twinsburg, OH), Zhang; Hai-Ren (Ellicott City, MD)
Assignee: Gilead Pharmasset LLC (Foster City, CA)
Filing Date:Mar 31, 2011
Application Number:13/076,842
Claims:1. A process for preparing an enantiomerically- or a diastereomerically enriched phosphorus-containing active, salt, or pharmaceutically acceptable salt thereof, of formula I-1: ##STR00204## which comprises the steps of: (a) reacting a protected or unprotected Active with a base to form a salt of said active and then reacting said salt with an enantiomerically- or a diastereomerically enriched compound of formula II-1 ##STR00205## wherein the Active is a nucleoside, a nucleoside-analog, or a non-nucleoside; wherein the nucleoside is selected from ##STR00206## ##STR00207## ##STR00208## ##STR00209## ##STR00210## wherein the nucleoside-analog is selected from ##STR00211## ##STR00212## wherein the non-nucleoside is selected from ##STR00213## ##STR00214## ##STR00215## ##STR00216## ##STR00217## ##STR00218## ##STR00219## ##STR00220## ##STR00221## wherein W is an aryl or --(CH.sub.2).sub.nSC(O)C(CH.sub.3).sub.m(CH.sub.2OH).sub.3-m; wherein n is 2 or 3 and m is 0, 1, 2, or 3; wherein LG is selected from the group consisting of halogen, tosylate, mesylate, triflate, acetate, trifluoromethylacetate, camphorsulfonate, 2-thioxobenzo[d]thiazol-3(2H)-yl, aryloxide, and aryloxide substituted with at least one electron withdrawing group; wherein R is a substituted or unsubstituted C.sub.1-30 alkyl, a substituted or unsubstituted C.sub.3-10 cycloalkyl, a substituted or unsubstituted C.sub.1-30 alkylaryl, a substituted or unsubstituted C.sub.2-10 alkenyl, a substituted or unsubstituted --OC.sub.1-30 alkyl, a substituted or unsubstituted C.sub.6-12 aryl; and wherein R' is a substituted or unsubstituted C.sub.1-30 alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted C.sub.1-30 alkylaryl, or a substituted or unsubstituted C.sub.6-12 aryl; and (b) optionally deprotecting the compound obtained in step (a) to obtain the enantiomerically- or diastereomerically-enriched phosphorous-containing active, salt, or pharmaceutically acceptable salt thereof of formula I-1, wherein the enantiomerically- or diastereomerically-enriched compound of formula II-1 is obtained by crystallization from a composition comprising: i. a first composition; ii. a leaving group precursor; iii. a non-nucleophilic base; and iv. a liquid composition; wherein the first composition comprises Rp-II-1 and Sp-II-1; and wherein the leaving group precursor is 2,4-dinitrophenol, 4-nitrophenol, 2-nitrophenol, 2-chloro-4-nitrophenol, 2,4-dichlorophenol, or pentafluorophenol.

2. The process of claim 1, wherein the Active is a nucleoside.

3. The process of claim 1, wherein R' is a C.sub.1-6alkyl or C.sub.3-7cycloalkyl.

4. The process of claim 1, wherein R is methyl or isopropyl and R' is a C.sub.1-6alkyl or C.sub.3-7cycloalkyl.

5. The process of claim 1, wherein LG is an aryloxide substituted with at least one electron withdrawing group.

6. The process of claim 1, wherein LG is selected from among 2-nitrophenoxide, 4-nitrophenoxide, 2,4-dinitrophenoxide, pentafluorophenoxide, 2-chloro-4-nitrophenoxide, 2,4-dichlorophenoxide, and 2,4,6-trichlorophenoxide.

7. The process of claim 1, wherein the Active is a nucleoside analog.

8. The process of claim 1, wherein the Active is a non-nucleoside.

9. The process of claim 1, wherein the enantiomerically- or diastereomerically enriched phosphorous-containing active, salt, or pharmaceutically acceptable salt thereof of formula I-1 has at least 90 mol % of one enantiomer or diastereomer and at most about 10 mol % of the other enantiomer or diastereomer.

10. The process of claim 9, wherein no chiral purification technique is used.

11. The process of claim 1, wherein the enantiomerically- or diastereomerically enriched phosphorous-containing active, salt, or pharmaceutically acceptable salt thereof of formula I-1 has at least 95 mol % of one enantiomer or diastereomer and at most about 5 mol % of the other enantiomer or diastereomer.

12. The process of claim 1, wherein LG is 2,4-dinitrophenoxide, 4-nitrophenoxide, 2-nitrophenoxide, 2-chloro-4-nitrophenoxide, 2,4-dichlorophenoxide, or pentafluorophenoxide.

13. The process of claim 12, wherein LG is 4-nitrophenoxide or pentafluorophenoxide.

14. The process of claim 12, wherein the non-nucleophilic base is triethylamine.

15. The process of claim 1, wherein the crystallization occurs at a temperature between about -10.degree. C. and about 40.degree. C.

16. The process of claim 1, wherein the non-nucleophilic base is potassium carbonate, cesium carbonate, di-isopropropylamine, di-isopropylethylamine, triethylamine, quinuclidine, napthalene-1,8-diamine, 2,2,6,6-tetramethylpiperidine, 1,8-diazabicycloundec-7-ene, 4-dimethylamino-pyridine, pyridine, a 2,6-di-C.sub.1-6-alkyl-pyridine, a 2,4,6-tri-C.sub.1-6-alkyl-pyridine, or a mixture thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc